The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, positioning the program for potential expedited interaction with the agency during development. TRI-611 is described as an oral “molecular glue degrader” that targets ALK fusion proteins through targeted protein degradation, rather than classic ALK tyrosine kinase inhibition. TRIANA’s materials emphasize the unmet need in patients who have received two or more ALK tyrosine kinase inhibitors, including concerns such as resistance, central nervous system metastases, and tolerability. Fast Track is not an approval, but it can provide more frequent FDA meetings and, depending on criteria later met, eligibility for rolling review or Accelerated Approval/Priority Review. Mechanistically, the Fast Track coverage highlights a cereblon E3 ligase proximity approach designed to degrade ALK fusions independently of the kinase active site—an angle intended to address serial resistance that limits TKIs. For biotech developers, this is another signal that the FDA is engaging early with nontraditional targeted oncology modalities aimed at overcoming post-TKI resistance, especially in CNS-challenged disease settings.